世界卫生组织胰胆细胞病理学分类对胰腺内镜超声引导细针穿刺的风险分层
该研究回顾性分析了2014至2017年胰腺癌中心的2562例胰腺内镜超声引导细针穿刺标本,比较WHO与PSC分类的恶性绝对风险(AROM)及预后分层。结果显示囊性与实性病变的AROM差异显著,WHO IV类在囊性和实性中AROM均低,两种分类均可分层总生存概率。
要点
- 囊性与实性病变类型显著影响AROM,尤其对WHO I、II、III和V类。
- WHO IV类在囊性和实性病变中均显示较低的AROM。
- WHO和PSC分类均可分层总生存概率,包括新引入的WHO IV和V类。
核心结论
- 囊性与实性病变类型可显著影响AROM,尤其对非诊断性(I)、良性(II)、非典型(III)和WHO V类。
- WHO IV类在囊性和实性病变中均传达相似的较低AROM。
- 两种分类均可分层总生存概率,包括新引入的WHO IV和V类。
研究设计与样本
- 回顾性收集2014至2017年胰腺癌中心的胰腺内镜超声引导细针穿刺数据。
- 共纳入2562例,其中囊性病变411例(16%),实性病变2151例(84%)。
- 组织学确认率为43%(n=1101),良性病变中位随访时间为56个月。
主要发现
- WHO I-VII类总体AROM(%)分别为23、22、62、13、65、97和100。
- WHO I-VII类囊性AROM(%)分别为7、0、19、13、38、78和100。
- WHO I-VII类实性AROM(%)分别为50、29、70、15、100、99和100。
- PSC I-VI类总体AROM(%)分别为23、29、64、0(IVa)、60(IVb)、97和100。
- PSC I-VI类囊性AROM(%)分别为7、0、19、0、21、78和100。
临床怎么用
- 在解读胰腺内镜超声引导细针穿刺细胞病理时,应结合病变类型(囊性或实性)评估恶性风险。
- WHO IV类在囊性和实性病变中恶性风险均较低,可辅助临床决策。
- WHO和PSC分类均可用于分层患者的总生存概率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The World Health Organization (WHO) has recently published a classification for reporting pancreaticobiliary cytopathology with differences compared to the Papanicolaou Society of Cytopathology (PSC) classification. METHODS: Retrospective data were collected from pancreatic endoscopic ultrasound-guided fine-needle aspirations from 2014 to 2017 at a pancreatic cancer center. Absolute risk of malignancy (AROM), relative risk (to benign), performance characteristics, and overall survival were calculated for the entire cohort with comparison of cysts and solid lesions. RESULTS: In total, 2562 cases were included: 16% cyst (n = 411) and 84% solid (n = 2151). The histologic confirmation rate was 43% (n = 1101) and the median follow-up (for benign) was 56 months. For WHO I-VII, overall AROM (%) was 23, 22, 62, 13, 65, 97, and 100; cyst AROM was 7, 0, 19, 13, 38, 78, and 100; and solid AROM was 50, 29, 70, 15, 100, 99, and 100. For PSC I-VI, overall AROM (%) was 23, 29, 64, 0 (IVa), 60 (IVb), 97, and 100; cyst AROM was 7, 0, 19, 0, 21, 78, and 100; and solid AROM was 50, 35, 73, 0, 92, 99, and 100. The difference in relative risk for a cyst (vs. solid) overall was 0.38 for WHO and 0.26 for PSC. WHO and PSC categories showed stratification for the probability of overall survival. CONCLUSIONS: Cystic versus solid lesion type can dramatically affect AROM, particularly for nondiagnostic (I), benign (II), atypical (III), and WHO V categories. WHO IV conveys a similarly low AROM for cystic and solid types. Both classifications stratify the probability of overall survival, including the newly introduced categories WHO IV and WHO V.
引用
- Lui SK, Hargett I, Pharaa Z, et al. The World Health Organization classification of pancreaticobiliary cytopathology stratifies risk of malignancy and outcome for endoscopic ultrasound-guided fine-needle aspiration of the pancreas. Cancer Cytopathol. 2023. PMID: 37602886. doi:10.1002/cncy.22754
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。